Analysis of soluble interleukin-2 receptor as a prognostic biomarker in NMOSD and MOGAD

Klyscz, Philipp; Otto, Carolin; Ruprecht, Klemens; Asseyer, Susanna; Tiedt, Hannes Ole; Meisel, Christian; Bellmann-Strobl, Judith; Paul, Friedemann; Schindler, Patrick

Analysis of soluble interleukin-2 receptor as a prognostic biomarker in NMOSD and MOGAD

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 1MB
	MS Word (Supporting Information) 24kB

Item Type:	Article
Title:	Analysis of soluble interleukin-2 receptor as a prognostic biomarker in NMOSD and MOGAD
Creators Name:	Klyscz, Philipp, Otto, Carolin, Ruprecht, Klemens, Asseyer, Susanna, Tiedt, Hannes Ole, Meisel, Christian, Bellmann-Strobl, Judith, Paul, Friedemann and Schindler, Patrick
Abstract:	OBJECTIVE: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions. Here, we compared sIL-2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin-4-IgG-seropositive and seronegative (AQP4-IgG+/-) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL-2R for future attacks. METHODS: Retrospective analysis of real-world data of patients treated at Charité-Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4-IgG+NMOSD, 10 AQP4-IgG-NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow-up time was 40 (35) months. sIL-2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks. RESULTS: Serum sIL-2R was higher in AQP4-IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL-2R (HR = 9.07 [95% CI 1.37-60.01]) and CSF sIL-2R (HR = 3.27 [95% CI 0.61-17.45]) levels were predictive for subsequent attacks. INTERPRETATION: Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.
Keywords:	Biomarker, MOGAD, NMOSD, Soluble Interleukin-2 Receptor
Source:	Annals of Clinical and Translational Neurology
ISSN:	2328-9503
Publisher:	Wiley
Date:	5 September 2025
Official Publication:	https://doi.org/10.1002/acn3.70186
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year